

Claims

1. Use of pure boswellic acid, a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for preventing and/or combatting diseases which are caused by increased leucocytic elastase or plasmin activity or can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.
2. Use according to claim 1, characterized in that use is made in the case of pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase activity, and in the case of tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.
3. Use according to claim 1 or 2, characterized in that use is made intraperitoneally, orally, buccally, rectally, intramuscularly, topically, subcutaneously, intraarticularly, intravenously or inhalationally.
4. Use according to at least one of claims 1 to 3, characterized in that use is made in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.
5. Use of pure boswellic acid or a physiologically acceptable salt, a derivative, a salt of the derivative or a plant preparation containing boswellic acid for the preparation of a medicament for treating diseases which are caused by increased leucocytic elastase or plasmin activity or which can be treated by the inhibition of normal leucocytic elastase or plasmin activity, in human or veterinary medicine.

09011977-061598

6. Use according to claim 5, characterized in that a medicament is produced for the treatment of pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis, which are caused by increased leucocytic elastase activity, and in the case of tumors and neoplasm or tumor metastases which are caused by increased plasmin activity.

7. Use according to claim 6, characterized in that use is made for the preparation of a medicament for the intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous or inhalational administration.

8. Use according to claim 6 or 7, characterized in that use is made for the preparation of a medicament in the form of tablets, dragees, capsules, solutions, emulsions, ointments, creams, inhalants, aerosols or suppositories.

9. Use according to at least one of claims 1 to 8, characterized in that use is made together with other chemically pure medicinal substances, and/or plant medicaments.

add A

add C₄

add D₆

add F₃

09011977-061508